Induction of intercrypt goblet cells upon bacterial infection: a promising therapeutic target to restore the mucosal barrier DOI Creative Commons
Renaud Léonard,

Ewa Pasquereau-Kotula,

Edwige Madec

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Nov. 14, 2024

Intestinal mucins play a crucial role in the mucosal barrier, serving as body's initial defense against microorganisms. However, how host regulates secretion and glycosylation of these response to bacterial invasion remains unclear. Our study demonstrates that when exposed Streptococcus gallolyticus (SGG), gut pathobiont, mucosa promptly adjusts behavior specialized goblet cells (GCs) located middle crypts. A subset undergoes remodeling, becoming intercrypt (icGCs), which do not detach from surface but instead migrate along spaces while secreting mucus impermeable pathogens. Significantly, non-piliated SGG mutant unable bind fails induce icGCs, allowing its translocation through submucosa. Interestingly, closely related nonpathogenic bacterium, SGM, able mucus, also triggers differentiation GCs into icGCs. This discovery opens new avenues for treating patients with "leaky gut" observed intestinal diseases such inflammatory bowel metabolic disorders, history repeated antibiotic use. Utilizing mucus-adherent probiotics icGCs represents promising strategy reinforcing barrier.

Language: Английский

Antibiotics damage the colonic mucus barrier in a microbiota-independent manner DOI Creative Commons

Jasmin Sawaed,

Lilach Zelik, Y. Levin

et al.

Science Advances, Journal Year: 2024, Volume and Issue: 10(37)

Published: Sept. 11, 2024

Antibiotic use is a risk factor for development of inflammatory bowel diseases (IBDs). IBDs are characterized by damaged mucus layer, which does not separate the intestinal epithelium from microbiota. Here, we hypothesized that antibiotics affect integrity barrier, allows bacterial penetrance and predisposes to inflammation. We found antibiotic treatment led breakdown colonic barrier penetration bacteria into layer. Using fecal microbiota transplant, RNA sequencing followed machine learning, ex vivo secretion measurements, germ-free mice, determined induce endoplasmic reticulum stress in colon inhibits microbiota-independent manner. This antibiotic-induced flaw translocation microbial antigens circulation, exacerbation ulcerations mouse model IBD. Thus, might predispose inflammation impeding production.

Language: Английский

Citations

10
Commensal fungi, a force to be reckoned with DOI
Dingjiacheng Jia,

Shujie Chen

Cell Host & Microbe, Journal Year: 2025, Volume and Issue: 33(1), P. 6 - 8

Published: Jan. 1, 2025

Language: Английский

Citations

0
Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay DOI Creative Commons
Yaxin Liu, Xinru Li, Yuchao Chen

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: March 25, 2025

Fecal microbiota transplantation (FMT) represents a therapeutic approach that directly regulates the gut of recipients, normalizes its composition and reaping rewards. Currently, in addition to general application treating Clostridium difficile ( C. ) infection (CDI), FMT treatment has also been extended fields other gastrointestinal diseases, infections, gut-liver or gut-brain axis disorders, metabolic diseases cancer, etc. Prior FMT, rigorous donor screening is essential reduce occurrence adverse events. In addition, it imperative evaluate whether recipient can safely effectively undergo treatment. However, efficacy influenced by complex interactions between recipient, degree engraftment not necessarily positively related with success rate FMT. Furthermore, an increasing number novel factors affecting outcomes are being identified recent clinical trials animal experiments, broadening our understanding This article provides comprehensive review scenarios influencing safety from aspects both donors summarizes how these emerging regulatory be combined predict patients undergoing

Language: Английский

Citations

0
The Estonian Biobank’s journey from biobanking to personalized medicine DOI Creative Commons
Lili Milani, Maris Alver, Sven Laur

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 5, 2025

Abstract Large biobanks have set a new standard for research and innovation in human genomics implementation of personalized medicine. The Estonian Biobank was founded quarter century ago, its biological specimens, clinical, health, omics, lifestyle data been included over 800 publications to date. What makes the biobank unique internationally is translational focus, with active efforts conduct clinical studies based on genetic findings, explore effects return results participants. In this review, we provide an overview Biobank, highlight strengths studying variation quantitative phenotypes health-related traits, development methods frameworks bringing into clinic, role as driving force implementing medicine national level beyond.

Language: Английский

Citations

0
'Smart', microbiome-sparing antibacterial therapy with a focus on the novel Lolamicin: an overview DOI Creative Commons
Ahmad Reza Rezaei,

Furkan Ates,

Artur Sulik

et al.

Infection, Journal Year: 2025, Volume and Issue: unknown

Published: April 12, 2025

Antibiotic resistance (AR) is an escalating worldwide health emergency, requiring inventive strategies for antibiotic treatment. This review examines the tactics used in designing smart antibiotics, with a specific emphasis on mechanism of action lolamicin, newly developed microbiome-sparing antibiotic. We recent advances development, particularly those aiming to preserve gut microbiome while effectively targeting pathogens. The study focuses lolamicin's selective mechanism, its inhibition LolCDE complex Gram-negative bacteria. Lolamicin works by blocking complex, which crucial transporting lipoproteins Gramnegative It offers significant improvement compared conventional antibiotics and other microbiomesparing options safeguarding reducing development resistance. However, limited range effectiveness - namely against certain harmful bacteria such as Pseudomonas aeruginosa possibility becoming resistant it, remain areas concern. presents hopeful resolution selectively attacking leaving beneficial flora unharmed. Further investigation rigorous clinical testing are essential fully harness promise confirm long-term utility combating

Language: Английский

Citations

0
Living on the edge: Mucus-associated microbes in the colon DOI Creative Commons
Mihovil Joja, Erica T. Grant, Mahesh S. Desai

et al.

Mucosal Immunology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

The colonic mucus layer acts as a physicochemical barrier to pathogen invasion and habitat for mucus-associated microbes. This mucosal microbiome plays crucial role in moderating production, maintaining integrity, shaping the host immune response. However, unchecked mucin foraging may render vulnerable disease. To better understand these dynamics layer, it is essential advance fundamental knowledge on how commensals bind utilize well their interactions with both microbial neighbors. We present an overview of approaches surveying bacteria assessing mucin-utilizing capacity, alongside discussion limitations existing methods. Additionally, we highlight diet secretory immunoglobulin A interact bacterial community colon. Insights into this subset can guide therapeutic strategies optimally support modulate integrity.

Language: Английский

Citations

0
Diverse landscape of genomic research within the Estonian Biobank DOI
Reedik Mägi

Human Molecular Genetics, Journal Year: 2025, Volume and Issue: unknown

Published: May 2, 2025

Language: Английский

Citations

0
Induction of intercrypt goblet cells upon bacterial infection: a promising therapeutic target to restore the mucosal barrier DOI Creative Commons
Renaud Léonard,

Ewa Pasquereau-Kotula,

Edwige Madec

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Nov. 14, 2024

Intestinal mucins play a crucial role in the mucosal barrier, serving as body's initial defense against microorganisms. However, how host regulates secretion and glycosylation of these response to bacterial invasion remains unclear. Our study demonstrates that when exposed Streptococcus gallolyticus (SGG), gut pathobiont, mucosa promptly adjusts behavior specialized goblet cells (GCs) located middle crypts. A subset undergoes remodeling, becoming intercrypt (icGCs), which do not detach from surface but instead migrate along spaces while secreting mucus impermeable pathogens. Significantly, non-piliated SGG mutant unable bind fails induce icGCs, allowing its translocation through submucosa. Interestingly, closely related nonpathogenic bacterium, SGM, able mucus, also triggers differentiation GCs into icGCs. This discovery opens new avenues for treating patients with "leaky gut" observed intestinal diseases such inflammatory bowel metabolic disorders, history repeated antibiotic use. Utilizing mucus-adherent probiotics icGCs represents promising strategy reinforcing barrier.

Language: Английский

Citations

2